Nonvalvular atrial fibrillation
Conditions
Interventions
Control group-man:Before start taking rivaroxaban.
Control group-woman:Before start taking rivaroxaban.
5mg group-man:Orally taken rivaroxaban 5mg/day for at a week.
5mg group-woman: Orally taken rivaroxaban 5mg/day for at a week.
10mg group-man:Orally taken rivaroxaban 10mg/day for at a week.
10mg group-woman:Orally taken rivaroxaban 10mg/day for at a week.
15mg group-man: Orally taken rivaroxaban 15mg/day for at a week.
15mg group-woman:Orally taken rivaroxaban 15mg/day for at a week.
Sponsors
Guangzhou First People's Hospital
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria for non-valvular atrial fibrillation; 2. Aged >= 60 years; 3. Patients who have not taken anticoagulant drugs before, newly diagnosed paroxysmal or persistent atrial fibrillation, and decide to start oral rivaroxaban; 4. The patients voluntarily accepted the study and signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Low body weight patients (BMI<18kg/m^2); 2. Severe organic valvular heart disease that causes hemodynamic changes; 3. There is a history of artificial heart valve implantation in the past; 4. There is a plan to perform cardioversion (electrical or pharmacological) during the trial; 5. Transient atrial fibrillation caused by reversible diseases (such as hyperthyroidism, recent surgery, myocardial infarction); 6. Patients with chronic active bleeding disease or gastrointestinal tract within the past 6 months, with high risk of bleeding and unable to tolerate dose changes of rifaxaban; 7. Severe, disabling stroke, trauma, surgery or any type of stroke within the past 2 weeks within the past 3 months; 8. Patients with severe cardiac insufficiency (NYHA class IV), or severe liver and kidney damage. Liver function damage was defined as glutathione and aspartate aminotransferase increased by more than 3 times higher than the normal upper limit; severe renal function damage was defined as GFR<30ul/min/1.72m^2; 9. Patients with leukemia, hemophilia and hemolytic anemia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anti-Xa factor activity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Prothrombin time;International normalized ratio;Prothrombin activity;Chemokines; | — |
Countries
China
Contacts
Public ContactYang Chongzhe
Guangzhou First People's Hospital
Outcome results
None listed